摘要
目的:比较国产与进口氯吡格雷在急性冠脉综合征(ACS)治疗中的成本-效果。方法:将80例ACS患者随机均分为进口氯吡格雷联合阿司匹林组(A组)和国产氯吡格雷联合阿司匹林组(B组),对比2组患者的临床疗效、不良反应及治疗费用,并进行成本-效果分析。结果:治疗1年后,2组总有效率分别为90%、87.5%,不良反应发生率均为7.5%,差异均无统计学意义(P>0.05)。A、B组成本分别为7948.2、5188.2元,成本-效果比分别为8831.3、5829.4(P<0.05)。结论:国产与进口氯比格雷治疗ACS疗效相似,但国产氯比格雷经济性较好。
OBJECTIVE： To compare the therapeutic efficacy of domestic clopidogrel vs. imported clopidogrel in the treatment of acute coronary syndrome （ACS）. METHODS： 80 patients were randomly assigned into imported clopidogrel （Plavix）combined with aspirin group （group A） and domestic clopidogrel （Taijia） combined with aspirin group （group B） with 40 cases in each group. The clinical efficacy, side effects and costs of 2 groups were compared, and cost-effectiveness analysis was conducted in 2 groups. RESULTS： After 1 year treatment, the total effective rate, and the incidence of side effects was 90% and 87.5%, 7.5% and 7.5% （P〉0.05） ; the costs and cost-effectiveness ratio of 2 groups were 7 948.2 and 5 188.2 yuan, 8 831.3 and 5 829.4（P〈 0.05）, respectively. CONCLUSION： Group A is similar to group B in therapeutic efficacy, while the cost of group B is lower than that of group A. Therefore,the regime of group B is optimal one for the treatment of ACS.
出处
《中国药房》
CAS
CSCD
2012年第40期3801-3803,共3页
China Pharmacy
